Shares of Novo Nordisk tumbled Monday after the Danish drugmaker said U.S. regulators want to see a new study before they can finish their review of two diabetes treatments with a long-acting insulin.
The company said Sunday that the Food and Drug Administration requested information from a study that looks at cardiovascular health before it makes a decision on Tresiba and Ryzodeg, which both use the insulin degludec.
Novo Nordisk said it was surprised and disappointed by the decision. The company plans to provide the requested data, but it probably will not be able to do so this year. The request could delay U.S. approval by up to five years, Jefferies analyst Jeffrey Holford said in a research note.


JOIN THE DISCUSSION | Register here
We welcome comments. Please keep them civil, short and to the point. ALL CAPS, spam, obscene, profane, abusive and off topic comments will be deleted. Repeat offenders will be blocked. Thanks for taking part — and abiding by these simple rules. A thorough explanation of rules of conduct can be found in our Terms of Service. If you have any questions, including why your comment may not be showing immediately after you submit it, be sure to visit the commenting FAQ.